Matthew Kurian, Executive Committee Member at KYSCO, shared on LinkedIn:
“Excited to be attending my first ESMO – European Society for Medical Oncology this year in Madrid!
Here are my Top 5 breast cancer abstracts I’ll be watching at ESMO2026!
Breast cancer is moving incredibly fast with 10 new FDA indications already since May 2026, with more potentially practice changing data to come in Madrid!
Plenty to discuss. I will continue to post about other abstracts over the next few weeks I am interested in as well!
Looking forward to the science and seeing many friends and colleagues soon! DM if you’d like to meet!
My Top 5 Breast Cancer Abstracts to Watch at ESMO26
Madrid, Spain | October 23–27, 2026
- TALENT (LBA23) – Final results: neoadjuvant T-DXd with or without anastrozole, or in sequence with chemotherapy, in HR+, HER2-low early breast cancer.
- NATALEE (LBA25) – Adjuvant ribociclib + NSAI in HR+/HER2– early breast cancer: 6-year overall survival and efficacy outcomes.
- KEYNOTE-B49 (LBA51) – Phase III pembrolizumab vs placebo plus chemotherapy in HR+/HER2– advanced breast cancer.
- FINER (LBA14) – Overall survival with fulvestrant + ipatasertib in HR+/HER2– metastatic breast cancer.
- PANKU-Breast01 (LBA50) – Phase III izalontamab brengitecan in previously treated unresectable locally advanced or metastatic HR+/HER2– breast cancer.”
Other articles about ESMO on OncoDaily.